CHMP Multaq Meeting Took Place on September 2, 2011

The European Medicines Agency’s Committee on Medicinal Products for Human Use met Sept. 2 to talk about the ongoing review of Multaq’s benefits and risks.

At the request of the European Commission, Multaq’s most recent review started back in January of this year. The review request was issued after two reports of liver damage from patients taking the drug. In July, the review was extended to include what effect the medication had on the heart, blood vessels and lungs. This newest meeting was called because of new information on the safety risks associated with Multaq, which wasn’t available before the committee’s last gathering.

This new safety information has the assessors now analyzing the data in a more in-depth manner. They were also asking for more information from the marketing authorization holder as they prepared for the meeting on Friday. Multaq has been approved for European use since 2009. It is to be used as a treatment for patients who suffer from atrial fibrillation, which is a condition that causes the upper chambers of the heart to beat in an irregular manner. Now that the most recent meeting has taken place, many are waiting for the results of that meeting to be made public so that they can know what the next steps to take will be regarding prescription Multaq use.

If you or a family member have suffered from liver failure or heart-related complications after taking Multaq, contact attorney Greg Jones today for a free consultation. I am experienced at fighting Multaq lawsuits and may be able to help you recover money for your injuries.

Share this article

You May Also Like

All Rights Reserved 2016